FDA Approvals
7 articles on FDA Approvals, written by Shotlee and medically reviewed for clinical accuracy.
Generic Ozempic Semaglutide Gets Tentative USFDA Approval; OneSource CDMO Par...
A generic version of Ozempic semaglutide has received tentative USFDA approval, marking a key step toward affordable GLP-1 therapy. Orbicular spearheaded product development, partnering with OneSource Specialty Pharma as the CDMO for reliable U.S. market manufacturing. This collaboration promises steady commercial supply from an FDA-approved site.
5 min read
FDA Approves Foundayo Weight Loss Pill, Igniting GLP-1 Showdown
The FDA has approved Foundayo weight loss pill from Eli Lilly on April 1 (ET), introducing a flexible oral GLP-1 option for adults with obesity or weight-related conditions—no food or water restrictions needed. Trial data shows superior weight loss over Rybelsus, averaging 15-20 pounds vs. 8-11 pounds in diabetes patients. This approval sets up a new showdown in the GLP-1 market dominated by injections like Wegovy and Zepbound.
5 min read
FDA Approves Eli Lilly's Foundayo GLP-1 Pill, Stock Jumps 5%
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
4 min read
Wegovy Pill May Expand Access to Obesity Treatments
The United States Food and Drug Administration has greenlit the initial tablet form of a GLP-1 drug designed for shedding pounds, which might considerably broaden availability of obesity therapies. Produced by the Danish firm Novo Nordisk, this daily Wegovy pill is set to debut in early January, with clinical trial participants averaging a 16.6% drop in body weight.
1 min read
A GLP-1 Weight Loss Pill Approaches. Here's Its Comparison to Injections
Injectable GLP-1 medications have revolutionized obesity management, and now an oral option is emerging. The FDA has approved a pill version of semaglutide for weight loss and cardiovascular risk reduction.
1 min read
Wegovy Pill Approved by FDA for Weight Management: Key Details
The Food and Drug Administration (FDA) has given the green light to Novo Nordisk's oral Wegovy pill, a semaglutide medication, for weight loss management. This new option offers an alternative to injectable medications for individuals struggling with obesity or overweight conditions. Clinical trials have demonstrated significant weight loss results.
3 min read
FDA Approves New Treatments: Oral Semaglutide & Lupus Nephritis Drug
The FDA has recently approved new treatments for two significant health challenges: cardiovascular risk reduction in type 2 diabetes and lupus nephritis. Learn about the potential benefits of these advancements and what they mean for patient care.
3 min read